Trial reportAnnals of the American Thoracic Society2026
Rodatristat ethyl decreases activity in pulmonary arterial hypertension: results from the ELEVATE-2 trial.
Trial report in Annals of the American Thoracic Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04712669 (A Phase 2, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 2, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension
Who cites it
2 citing papers in PubMed.
- Remote exercise assessment in pulmonary hypertension.Current opinion in pulmonary medicine · 2026Review
- Longitudinal Remote 6-Minute Walk Distance and Cardiac Effort Using Wearable Sensors in Pulmonary Hypertension.Pulmonary circulation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
rationaleWearable devices provide an objective measurement of activity in the home setting and are complementary to 6-minute walk distance. Patients with pulmonary arterial hypertension (PAH) have low daily activity time, which is likely related to physiologic impairment and behavioral changes. Actigraphy may be a functional outcome assessment capable of detecting changes in activity mediated by improvement in physiology in a therapy trial.
objectivesELEVATE-2 was a phase 2 trial evaluating rodatristat ethyl versus placebo in PAH. We hypothesized rodatristat ethyl would improve measures of activity, specifically peak steps, at week 24, and further that changes in actigraphy measures would correlate with changes in stroke volume index.
methodsELEVATE-2 was a randomized, double-blinded, placebo-controlled trial. All participants wore an ActiGraph on their wrist. We compared changes in average peak 5-minute steps (steps during the most active 5 minutes of a day, whether or not consecutive), daily steps, moderate activity time, and vigorous activity time at baseline, week 12, and week 24. Linear mixed methods with repeated measures were performed to assess treatment-time interaction at week 24, and least squares means were used to compare groups. Linear regression was performed to evaluate the changes in stroke volume index on activity parameters.
resultsOf the 108 participants, 100 were included in the analysis. Adjusted least squares mean showed that peak 5-minute steps (-49 steps [95% CI, -80 to -18]), moderate activity time (-17.3 minutes/day [95% CI, -29.3 to -5.3]), and daily steps (-656 [95% CI, -1171 to -140]) all decreased at week 24 after treatment with rodatristat ethyl compared to placebo. Peak 5-minute steps were weakly associated with changes in stroke volume index (0.74 [95% CI, 0.11-1.37]).
conclusionsRodatristat ethyl reduced multiple activity parameters in this small, randomized multicenter study. Peak steps, daily steps, and moderate activity time seem to capture different aspects of movement in the home setting. Activity parameters were not strongly associated with resting hemodynamics, underscoring the influence of behavioral and external factors on activity. CLINICAL TRIALS REGISTRATION: NCT04712669.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.